Shigella vaccine - LimmaTech Biologics

Drug Profile

Shigella vaccine - LimmaTech Biologics

Alternative Names: Flexyn2a; GVXN-SD133; Multivalent Shigella vaccine - GlycoVaxyn; Shigella dysenteriae vaccine - GlycoVaxyn; Shigella flexneri 2a vaccine - GlycoVaxyn; Shigella flexneri vaccine - GlycoVaxyn; Shigella multivalent vaccine - GlycoVaxyn; Shigella sonnei vaccine - GlycoVaxyn; Shigella vaccine - GlycoVaxyn; Vaccine biconjugate Shigella dysenteriae - GlycoVaxyn

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator GlycoVaxyn
  • Developer GlycoVaxyn; Johns Hopkins Bloomberg School of Public Health; LimmaTech Biologics
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Shigella infections
  • Discontinued Intestinal infections

Most Recent Events

  • 10 Aug 2016 Discontinued - Phase-I for Intestinal infections caused by Shigella (Prevention, In adults) in Switzerland (IM)
  • 10 Aug 2016 Shigella vaccine - LimmaTech Biologics receives Fast Track designation for Shigella infections (Prevention, In adults) in USA before August 2016 (IM,Injection) (LimmaTech Biologics communication, August 2016)
  • 01 Sep 2015 GlycoVaxyn in collaboration with Wellcome Trust and Naval Medical Research Center completes phase I trial for Shigella infections (Prevention, In adults) in USA (NCT02388009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top